Objectives: We showed previously that stromal cellÀderived factor 1 (SDF-1) is a substrate of cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) and exerts regenerative properties on acute lung ischemia-reperfusion injury on CD26/DPP4 inhibition. Here, we extend our studies to test whether an intermediate recovery of lung transplants from ischemia/reperfusion injury by CD26/DPP4 inhibition can be achieved for up to 14 days.
Results: Cold ischemic time of 18 hours with vildagliptin preconditioning elevated lung SDF-1 levels (P ¼ .0011) and increased interleukin-10-producing macrophages (P ¼ .0165) compared with the control. SDF-1 reduced macrophage-derived TNF-a (P ¼ .0248) in vitro. Five hours after Tx, vildagliptin significantly reduced macrophages and neutrophils (P ¼ .0306), decreased ICAM-1 expression (P ¼ .002), and improved transplant oxygenation (P ¼ .0181). Seven days after Tx, grafts were preserved on CD26/DPP4-inhibition: perivascular macrophages (P ¼ .0046) and TNF-a (P ¼ .0013) were reduced as well as T and B cells. ICAM-1 was absent in CD26/DPP4-inhibited grafts at all time points.
Conclusions: This study proves an intermediate improvement of ischemia/ reperfusion-injured lung transplants by the CD26/DPP4-inhibitor vildagliptin up to 14 days. Enhanced levels of SDF-1 induced an anti-inflammatory effect on a cellular and protein level, and render CD26/DPP4 inhibition preconditioning effective for the protection from lung ischemia/reperfusion injury. (J Thorac Cardiovasc Surg 2017;153:713-24)
Vildagliptin induces intermediate lung transplant improvement from ischemia/reperfusion injury.
Central Message
Preconditioning with the cluster of differentiation 26/dipeptidylpeptidase 4 inhibitor vildagliptin proved to be effective for an attenuation of ischemia/reperfusion injury up to 14 days.
Perspective
Preconditioning with the cluster of differentiation 26/dipeptidylpeptidase 4 inhibitor vildagliptin provides intermediate improvement of lung transplants from ischemia/reperfusion injury for up to 14 days. Proposed effector mechanisms are enhanced interleukin-10Àproducing macrophages, reduced adhesion molecules, and reduced immune cells infiltration. We suggest vildagliptin as an effective compound for donor lung preconditioning for the attenuation of ischemia/reperfusion injury.
See Editorial Commentary page 725.
See Editorial page 711. 1 CD26/DPP4 functions both as a co-stimulatory molecule for T cells and has exopeptidase activity via an extramembranous catalytic domain. Yet, the physiologic functionality of CD26/DPP4 hinges on both. [2] [3] [4] Several key cytokines, chemokines, and neuropeptides are susceptible to DPP4 cleavage. 3, 5 One such is chemokine stromal cellÀderived factor-1 (SDF-1), 6 a key peptide for the recruitment and homing of bone marrowÀderived regenerative stem cells. 7 We have shown recently that the treatment of a mouse lung transplant recipient with a CD26/DPP4 inhibitor (vildagliptin) enhanced the levels of SDF-1 within transplanted lungs. Increased SDF-1 resulted in increased regenerative progenitor cell infiltration of the engrafted organ and recovery from ischemia/reperfusion (I/R) injury at 48 hours after transplantation (Tx) . 8 This was the first proof that CD26/DPP4 inhibition can indeed improve I/R injury via SDF-1-mediated effects. Our findings, however, were limited to 48 hours post-Tx, a short time range that usually is chosen by the majority of researchers for the investigation of I/R injury. This short time period, however, does not provide the proof for a definite and sustained benefit and function of the graft. Short-term recovery from I/R injury seems to be only beneficial when there is a long-term functionality of the transplant, but the evidence from the literature is scarce with regard to a sustained attenuation of I/R injury.
To fill this gap of knowledge and to test whether a longer protective effect by CD26/DPP4-inhibition and its substrate SDF-1 can be achieved, we here evaluated the treatment with the CD26/DPP4 inhibitor vildagliptin for up to 14 days on I/R-injured lungs. To this end, we preconditioned the organ with vildagliptin and analyzed the function and morphology of the engrafted organ immediately after cold ischemia (CI), as well as 5 hours, 7 days, and 14 days after orthotopic mouse single-lung Tx.
MATERIALS AND METHODS Animals
Male wild-type (C57BL/6; Charles River, Germany) mice were used for all experiments. Breeders of CD26À/À mouse (on a C57BL/6 background) were obtained from Taconic (Taconic, Bomholt, Denmark) with approval from Dr D. Marguet (Centre d'Immunologie de Marseille Luminy-INSERM, Marseille Luminy, France). Animals were fed a standard diet with water and food ad libitum and were kept under constant environmental conditions. They received adequate care in strict accordance with the Principles of Laboratory Animal Care (National Institutes of Health Publication No. 85-23, promulgated in 1985, most recently revised in 1996).
Experimental Setup for Mouse Lung Tx
Orthotopic left single-lung Tx between a syngeneic mouse strain (C57BL/6) was performed as we described in detail previously (Video 1). 9 Donor grafts were exposed to 18 hours of CI time before Tx with or without intragraft preconditioning by vildagliptin (1 mg/mL in saline: custom synthesized by GLSynthesis, Inc, Worcester, Mass). Preconditioning of the donor organ was accomplished by perfusing the aforementioned solution via the pulmonary artery during organ recovery as we usually do for regular donor organ perfusion. To avoid a remote effect VIDEO 1. Orthotopic left single lung transplantation: preparing of the hilar structures of the left donor lung (artery, bronchus, and vein), dissecting them from each other and equipping them with a plastic cuff. This prepared donor lung will then be implanted into the recipient by introducing the cuffed donor structures into the respective recipient artery, bronchus, and vein. After opening the newly formed anastomoses, a functional lung transplant is available for post-transplant analyses. Video available at: http://www.jtcvsonline.org/article/S0022-5223 (16) To achieve proper measurements by scientific means, we used the samples from repeated experiments for the assessments of SDF-1 and interleukin-10 (IL-10; n ¼ 3 for both control and vildagliptin groups) as well as fluorescence-activated cell sorting (FACS) analysis (n ¼ 3 for na€ ıve, n ¼ 5 for control and vildagliptin). We repeated the same experiment separately to assess different values of interested. The relevant information for the number of samples of each experiment is described detailed in the figure legends. During each time point of harvest, plasma samples were analyzed for tumor necrosis factor-a (TNF-a) measurement. All experimental Tx procedures were performed at the microsurgical laboratory of the Division of Thoracic Surgery at University Hospital Zurich.
Histology and Immunohistochemistry
Formalin-fixed and paraffin-embedded samples were stained by hematoxylin and eosin staining. Immunohistochemistry was performed on the samples at 5 hours after Tx (n ¼ 5 for control and vildagliptin groups), 7 days (n ¼ 5 for control and vildagliptin groups, n ¼ 4 for CD26À/À group), and 14 days (n ¼ 4 for control and vildagliptin groups) after Tx to stain CD3 Expression of Intercellular Adhesion Molecule-1 (ICAM-1) by Immunofluorescence ICAM-1 antibody was obtained commercially (Abcam, Cambridge, Mass). Donor grafts were embedded in paraffin, and sections were deparaffinized in xylene followed by treatment in 100% ethanol, 95% ethanol, 80% ethanol, and 50% ethanol (5 minutes, 2 times each). Tissue sections were then rinsed with water and 13 phosphate-buffered saline buffer. Antigen retrieval was performed by boiling in antigen unmasking solution (Vector Laboratories, Inc, Burlingame, Calif) for 30 minutes followed by cooling the samples to room temperature.
Tissue sections were washed and permeabilized and then stained for ICAM-1 (1:200). Tissue sections from each experimental time points including 18 hours of CI (n ¼ 3 for control and vildagliptin groups), 7 days (n ¼ 5 for control and vildagliptin groups), and 14 days (n ¼ 3 for control and vildagliptin groups) after Tx were used and the fluorescent signal from 5 regions within each sample were evaluated. Images were acquired with a Zeiss Meta 510 laser scanning confocal and multiphoton microscope with Zeiss 2007 software (Zeiss, Inc, Thornwood, NY). All immunofluorescence analyses were performed at the Institute for Environmental Medicine and Department of Physiology, University of Pennsylvania Perelman School of Medicine (Philadelphia, Pa).
Analysis of Protein Expression
Samples were homogenized in lysis buffer containing a protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany), phosphatase inhibitor cocktail 3, 50 mM Tris, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid, and 0.5 % NP-40 (Sigma-Aldrich, Buchs, Switzerland). Protein concentration was determined with the Bradford protein assay (BioRad, Hercules, Calif). The expressions of TNF-a, SDF-1, and IL-10 were assessed by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Abingdon, United Kingdom). For ICAM-1 western blotting (4%-20% gradient gel, antibody dilution: 1:2000), reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis was performed and samples (n ¼ 3 for control, n ¼ 4 for vildagliptin) were blotted onto a polyvinylidene fluoride membrane. After secondary antibody binding, the detection was performed according to standard protocols with the ECL detection reagent (BioRad).
Assay for Enzymatic Activity of DPP4
DPP4-like enzymatic activity was measured in the tissue lysate from control (n ¼ 5) and vildagliptin (n ¼ 5) groups after 18 hours of CI with the use of glycyl-prolyl-4-methoxy-b-naphthylamide. To summarize, in a 96-well plate, 10-mL samples were mixed with 0.5 mM glycyl-prolyl-4-methoxy-b-naphthylamide in 50 mM Tris buffer, pH 8.3, in a final volume of 110 mL. DPP4-like activity was determined kinetically for 20 minutes at 37 C via measurement of the velocities of 4-Me-b-NA release (lex ¼ 340 nm, lem ¼ 430 nm) from the substrate (all reagents are from Sigma-Aldrich, Buchs, Switzerland).
Oxygen Saturation In Vivo
The functionality of the (transplanted) lung was evaluated by the measurement of saturated oxygen (PaO 2 /FiO 2 ratio) level in arterial blood samples. Blood samples were taken from the abdominal aorta (100 mL) for blood gas analysis and electrolyte measurement test (Epocal, Inc, Ottawa, Ontario, Canada) on respective reperfusion time points (5 hours [n ¼ 5 for control and vildagliptin groups], 7 days [n ¼ 3 for control and vildagliptin groups], and 14 days [n ¼ 5 for control and vildagliptin groups] after Tx) immediately before harvesting of the animal. The reason for not being able to take blood from the pulmonary vein is that transplant recipients do not tolerate occlusion of the contralateral lung. For the scientific validation of the method, we compared the experimental data with the values of normal na€ ıve mice.
Fluorescence-Activated Cell Sorting
Single-cell suspensions from mouse lungs of na€ ıve (n ¼ 3), 18 hours of CI control (n ¼ 5), and vildagliptin (n ¼ 5) groups were prepared as described previously. 10 In summary, lungs were cut and incubated in collagenase II (2 mg/mL: PAN Biotech, Aidenbach, Germany) solution (10% fetal bovine serum, 50 mg/mL gentamicin in RPMI 1640) for 30 minutes at 37 C. The collagenase reaction was stopped by adding 1 mL of 1 M ethylenediaminetetraacetic acid, and cells were then filtered through a 70-mm cell strainer. Antibodies for IL10-APC, F4/80-PE, CD4-FITC, CD8-PerCP, and NKp46-Alexa647 (all antibodies from BD Pharmingen, Allschwil, Switzerland) were used and subjected to flow cytometry with the BD FACSCanto II flow cytometer (BD Biosciences, San Jose, Calif).
In Vitro Analysis of SDF-1 Effect on Macrophage Activation
RAW 264.7 mouse macrophage cell line was maintained in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum, penicillin (120 mg/mL)/streptomycin (200 mg/mL). The cell line was seeded into 10-cm plates to reach 70% confluence. Two days after cell seeding, media were changed to serum-free conditions. Twelve hours later, cells were exposed to different concentrations of SDF-1 (0.1-100 ng/mL; R&D systems, Abingdon, United Kingdom). The supernatant was collected at 1, 3, 6, 12, 24, and 48 hours after SDF-1 treatment to measure TNF-a release. This experiment was repeated 3 times.
Statistical Analysis
Data are presented as means AE SD. Groups were compared with the Student t test for unpaired samples with Prism 4.0 (GraphPad Software, San Diego, Calif). A 2-sided P-value <.05 was considered as statistically significant. The threshold feature of this software was used to define a selected area, and the integrated intensity was measured within that region. Data were acquired from at least 3 independent samples and expressed in arbitrary units after normalizing for equal area. Data sets were compared with the Student t test, and results were considered statistically significant at P<.05.
RESULTS
The CD26/DPP4 Inhibitor Vildagliptin Induces Alternative Activation of Macrophages To test the susceptibility of donor lung grafts on CD26/DPP4 and the effect of CD26/DPP4-inhibition by vildagliptin on CI injury in grafts, we analyzed the activity of CD26/DPP4, levels of SDF-1, and IL-10 by ELISA and FACS within lung tissues exposed to 18 hours' CI time. The activity of CD26/DPP4 within the lung tissue was significantly reduced by vildagliptin preconditioning (Figure 1, A) . Levels of SDF-1, the substrate of CD26/DPP4, were significantly elevated 18 hours after CI in vildagliptin-preconditioned lungs (Figure 1, B) . Furthermore, vildagliptin-preconditioned lungs showed greater levels of IL-10 ( Figure 1, C) measured by ELISA and also IL-10 þ macrophages (F4/80 þ ) compared with controls after 18 hours of CI (Figure 1, D) . We could not find any changes of other types of cells including CD4 þ , CD8 þ , and NKp46 þ after 18 hours of CI ( Figure E1 ).
To further characterize the effect of SDF-1 on the activation of macrophages (activation of macrophages occurred spontaneously after Tx without additional stimulation), we used the macrophage cell line RAW 264.7 with increasing concentrations of SDF-1. This led to a significant reduction of TNF-a production at 24 hours (Figure 1, E) , supporting the hypothesis of alternative macrophages activation. Summarizing these data, we provided evidence that CD26/DPP4 enhances SDF-1 availability, which leads to increased levels of IL10Àproducing macrophages. This mechanism is proposed as the base for the observed results at later time points after Tx. 
Vildagliptin Preconditioning Reduces Short-Term I/ R Injury by Decreased Cell Infiltration
We tested the effect of vildagliptin preconditioning during the early phase of I/R injury (5 hours after lung Tx) on macrophage and neutrophil infiltration, on the expression of ICAM-1 within the graft and on oxygen saturation. The preconditioning by vildagliptin decreased the infiltration of inflammatory cells within the graft 5 hours after Tx. Numbers of macrophages (F4/80 þ ) (Figure 2 , A and C) and neutrophils (NE þ ) (Figure 2 , B and D) were significantly reduced by vildagliptin preconditioning. Accordingly, the expression of the adhesion molecule ICAM-1 decreased on vildagliptin treatment compared with controls (Figure 2, E) . The function of the graft, assessed by oxygen saturation levels (PaO 2 /FiO 2 ) in the arterial blood, was significantly improved 5 hours after Tx (Figure 2, F) . In summary, acute I/R injury was attenuated as the result of reduced numbers of inflammatory cells leading to a better functionality of transplants.
Vildagliptin Preconditioning Induces Improvement From I/R Injury at 7 Days After Tx
Assessing the lung transplants at a longer time point, namely 7 days, we could observe a slightly shrunken but still ventilated and macroscopically well-preserved transplant. The representative features of the organs show a viable and functioning status after assessing the lung transplants at 7 days of reperfusion on CD26/DPP4-inhibition (Figure 3, A) compared with controls showing a red and shrunken appearance (Figure 3, B) . Histologically, vildagliptin-treated transplants revealed a well preserved alveolar architecture (Figure 3 , C) in contrast to controls in which the alveolar space was collapsed ( Figure 3, D) ; however, vessels and airways were patent and open. Level of oxygen saturation in the arterial blood did not show differences among Tx groups (Figure 3, E) .
Vildagliptin Preconditioning Reduces Tx-Related Inflammation 7 and 14 Days After Tx
Transplants were assessed for macrophages (F4/80
, and neutrophils (NE þ ) at 7 days and 14 days post-Tx. Vildagliptin preconditioned or CD26À/À grafts showed a significantly reduced perivascular macrophage infiltration at 7 days after lung Tx (Figure 4, A) . In contrast, there was no difference in alveolar macrophage numbers. Levels of TNF-a in plasma samples of recipients showed that the inhibition of CD26/ DPP4 significantly reduced circulating TNF-a levels, which supports the finding of reduced inflammatory cell infiltrates (Figure 4, B) . Also, there was a reduced lymphocytic perivascular infiltration of T cells and B cells ( Figure E2 ). This anti-inflammatory effect by CD26/DPP4 inhibition could be observed within grafts up to 14 days after Tx, although to a lesser extent ( Figures 5 and E3) ; however, alveolar lymphocytes and neutrophils were not significantly reduced by CD26/DPP4 inhibition ( Figure E4 ).
The CD26/DPP4 Inhibitor Vildagliptin Reduces ICAM-1 Expression
Immunofluorescence imaging, carried out in a blinded manner, showed a clear and distinct difference in ICAM-1 expression between na€ ıve lungs and 18-hour CI-injured lungs as well as vildagliptin-preconditioned and CD26À/ À lungs across all the samples evaluated. Specifically, in vildagliptin-preconditioned or CD26À/À mice lung sections, ICAM-1 expression was low to absent after 18 hours CI, as well as 7 and 14 days after Tx compared with control specimens (Figure 6 , A-K).
DISCUSSION
In this study, we showed that experimental preconditioning with the CD26/DPP4 inhibitor vildagliptin provides not only short-term but also intermediate improvement of the ischemia-injured transplanted lungs up to 14 days after Tx. On inhibition by vildagliptin, we found enhanced SDF-1 levels in CI-injured lungs. These elevated SDF-1 levels were paralleled by an increase in IL-10Àexpressing macrophages. The amelioration of I/R injury was maintained by reduced ICAM-1 expression with reduced infiltration of immune cells, mainly macrophages.
It is well known that innate immune cells, such as macrophages and neutrophils, play a key role in I/R injury. 11, 12 Shortly after Tx, vildagliptin preconditioning induced a significant reduction of these cells, paralleled by an improvement of oxygenation in lung transplants. The reasonable explanation for this reduction of cell infiltration were the low to absent expression of ICAM-1 at all time points, the molecule being characteristic for the activation of the endothelial lining and the adhesion and transmigration of cells into the transplanted graft. 13, 14 In general, studies investigating I/R injury show effects after a short period of reperfusion, usually few hours, presuming that these effects persist; however, the current literature does not provide substantial analyses on the function and mechanisms beyond 48 hours. Because I/R injury also contributes to chronic lung allograft dysfunction, long-term results on recovery from primary graft dysfunction seems even more important. Our data demonstrate that even 7 days after Tx, primarily I/Rinjured grafts remain viable over time upon preconditioning with vildagliptin. According to our data, the cause of this long-term functionality of transplanted grafts seems to be related to a reduced-ICAM-1Àmediated lower infiltration of immune cells, not only of macrophages, but also of T cells and B cells, which showed a trend towards continued reduction over time.
Although we used a syngeneic mouse combination for Tx, T cells seemed to be involved after Tx. T cells are known to have some role in I/R-injury, 15 however, to a much lesser extent compared with an allogeneic experimental transplant setting. We could recently show that costimulatory blockade of CD26/DPP4 shows evidence that graft-infiltrating T cells are significantly diminished after treatment with vildagliptin. 16 Despite the lack of alloantigen in this study, it is well imaginable that the inhibition of the co-stimulatory activity of CD26/DPP4 is triggered by the I/R injury and thus contributed in part to the reduction of T-cell infiltrations.
We deem that the short-term as well as the intermediate graft amelioration is related to the effect initiated by the preconditioning of the graft: intragraft inhibition by vildagliptin leads to decreased SDF-1 degradation, thereby enhancing the protein concentration within the organ. SDF-1 is a substrate of CD26/DPP4 and has been shown to exert regenerative effects through various mechanisms in ischemic organs. 17 Zaruba and colleagues 18 and Theiss and colleagues 19 could show that a combination of DPP4 inhibition and administration of granulocyte-colony stimulating factor mediated cardiac regeneration through the SDF-1/CXCR4-axis. Our own group showed that increased levels of SDF-1 lead to a recruitment of regenerative CD34 þ stem cells, resulting in a recovery of I/Rinjured grafts up to 48 hours after experimental mouse lung Tx via inhibition of CD26/DPP4 of the recipient, 8 thus corroborating these results.
Beside the reduction of immune cells over time, another mechanism we propose here for the long-term recovery of I/R lung injury is that SDF-1 activates alternative (M2) rather than classical (M1) macrophages and thereby create an immune-protective milieu. There is evidence that CXCR4-positive macrophages polarize towards a M2 phenotype via the SDF-1/CXCR4-axis. 20 These macrophages seem to be important for regulating the inflammatory response. 21 Others have equally shown that SDF-1 production modulates the differentiation of monocytes toward immunosuppressive functions. 22 In line with these data, we could show by FACS analysis that macrophages produced IL-10, which reflects an alternative macrophage phenotype that exerts anti-inflammatory effects. This anti-inflammatory effect of IL-10 has been proven in septic conditions with endothelial leakage thereby attenuating injury, 23 but also downregulating posttransplant immune responses after orthotopic lung Tx. 24, 25 Other than macrophages, inducible regulatory T cells can be well responsible for IL-10 production as recently shown in mouse lung allograft rejection. 26 The decreased levels of TNF-a that we measured in engrafted organs additionally support the hypothesis that either classical macrophages were attenuated or alternative macrophages were activated, presumably also by increased levels of IL-10. In vitro analysis confirmed that increasing concentrations of SDF-1 were able to dampen the TNF-a secretion from macrophages (cell line RAW 264.7).
The mechanistic observations proposed here were based on the analysis of 18 hours' CI transplants. A potential drawback of this study is that we did not investigate these findings after reperfusion, for instance, if the presence of IL-10 þ macrophages persisted over time. Also, we could not find SDF-1 levels to be elevated during the 7-day experimental follow-up. CD26/DPP4 inhibition, however, seems to be effective in the preconditioning phase and induces prolonged effects through the expression of SDF-1, which was found to be increased immediately after CI and which seems to be sufficient to elicit long-term effects. Another obstacle was the impossibility to obtain reliable oxygenation data from I/R-injured control grafts after 18 hours of ischemia and 7 days of reperfusion. First, by taking systemic arterial blood draw, the function of both lungs was evaluated. We tried to overcome this hurdle by subtracting the oxygenation values of a na€ ıve mouse from a Tx recipient mouse. Second, from the appearance of at least some of the transplanted lungs, it is likely that the systemic arterial blood gas is measuring primarily the function of the na€ ıve lung, which falsifies an objective oxygenation measurement. This should be regarded as an important confounder.
A major advantage in our experimental approach of preconditioning of lung transplants by vildagliptin is that this CD26/DPP4 inhibitor is in safe clinical use as a long-term treatment of type 2 diabetes. 27 This makes vildagliptin an attractive compound for a further investigation for clinical studies.
